iShares Microcap ETF (IWC)

The company announced the acquisition of ad-tech firm IndiCue for up to $40 million in total consideration.

The company announced pricing for a $12 million public offering at an 8% discount to Thursday’s close.

The company said that it will continue to seek funding for the SER-155 Phase 2 study.

The company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives.

The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration.

The company signed an agreement with a major U.S. defense prime contractor to supply a subsystem that supports missile propulsion.

The company received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.

The company announced that it has decided to cease clinical development of its lead asset dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP).

The U.S. Food and Drug Administration cleared its Investigational New Drug application for SER-252, a therapy to treat patients with Parkinson’s disease.

The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer.

Retail optimism for One Stop Systems comes amid the company’s about $1.2 million pre-production order from a U.S. defense prime contractor announced last week.

The Food and Drug Administration said in a letter to the company that it is unable to approve its EBVALLO application in present form, citing inadequate evidence of effectiveness for accelerated approval.

Cineverse expects Giant Worldwide to contribute pro forma revenue of $15-17 million in fiscal year 2027.

Nutriband has agreed to sell 90% of its stake in its subsidiary Pocono Pharmaceuticals for $5 million.

Senti Biopharma shares rallied in premarket trading on Tuesday after its cancer treatment received a positive designation from the U.S. FDA.

The company said it will work with the agency to reach a resolution and expressed confidence in its clinical data.

HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity in this aggressive human model, the company said.